CervoMed is a clinical stage biotechnology company. Co. is developing its primary product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC). TSC is designed to selectively target and re-oxygenate the micro-environment of hypoxic cells, and can potentially be used in various indications, including stroke, oncology and cardiovascular disease. Co.'s oncology program targets TSC against treatment-resistant brain cancer. In addition to the TSC programs, Co. is exploring alternatives to capitalize upon its product candidate RES-529, a PI3K/Akt/mTOR pathway inhibitor for age-related macular degeneration. We show 5 historical shares outstanding datapoints in our CRVO shares outstanding history coverage, used to compute CRVO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CRVO market cap history over the course of time is important for investors
interested in comparing CRVO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CRVO versus a peer is one thing; comparing
CRVO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CRVO can fluctuate over the course of history.
With this page we aim to empower investors researching CRVO by allowing them to research the CRVO market cap history. |
Free CRVO Email Alerts:
Video: The Importance of Market Cap
